Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Öka patienternas engagemang i beslutsfattande vid bröstcancerkirurgi

23 september 2026 uppdaterad av: Alliance for Clinical Trials in Oncology

Öka socioekonomiskt missgynnade patienters engagemang i bröstcancerkirurgi Beslutsfattande genom ett gemensamt beslutsfattande intervention

This trial studies how well a breast cancer surgery decision aid works in increasing patient engagement in decision making for patients with newly diagnosed stage 0-III breast cancer. The trial also examines barriers to patient engagement even with the use of a decision aid, and if barriers are more likely to be experienced by socioeconomically disadvantaged patients.

Studieöversikt

Detaljerad beskrivning

The primary and secondary objectives of the study:

PRIMARY OBJECTIVES:

I. Test the effectiveness of a breast cancer surgery decision aid in increasing patient engagement in decision making (measured by knowledge and power) in clinics serving a high proportion of socioeconomically disadvantaged patients.

II. Test the extent to which the effect of a decision aid on patient engagement is mediated through the mitigation of barriers and determine if persistent barriers are disproportionately experienced by socioeconomically disadvantaged patients.

SECONDARY OBJECTIVES:

I. Characterize how persistent barriers influence patient engagement in decision making in order to identify targets for adjunct interventions that could be implemented in clinics serving a high proportion of socioeconomically disadvantaged patients.

Trial Design:

OUTLINE: This is a multi-site cluster randomized trial using a stepped wedge design. Ten clinics will be recruited for participation. All clinics will begin in the usual care arm. Clinics will be randomized to the timing with which they cross-over to the decision aid intervention, with new clinics crossing over every 10 weeks.

ARM I: usual care

ARM II: decision aid intervention

The only difference between patients enrolled before institutional crossover and patients enrolled after institutional crossover is those who are enrolled after institutional crossover will have been offered the decision aid as accepted practice in the clinic.

Studietyp

Interventionell

Inskrivning (Faktisk)

627

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Dublin, California, Förenta staterna, 94568
        • Epic Care-Dublin
      • Emeryville, California, Förenta staterna, 94608
        • Bay Area Breast Surgeons Inc
      • Emeryville, California, Förenta staterna, 94608
        • Epic Care Partners in Cancer Care
      • Martinez, California, Förenta staterna, 94553-3156
        • Contra Costa Regional Medical Center
      • Oakland, California, Förenta staterna, 94609
        • Alta Bates Summit Medical Center - Summit Campus
      • Oakland, California, Förenta staterna, 94609
        • Bay Area Tumor Institute
      • Walnut Creek, California, Förenta staterna, 94597
        • Epic Care Cyberknife Center
    • Georgia
      • Augusta, Georgia, Förenta staterna, 30912
        • Augusta University Medical Center
    • Hawaii
      • Honolulu, Hawaii, Förenta staterna, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, Förenta staterna, 96817
        • The Cancer Center of Hawaii-Liliha
      • Honolulu, Hawaii, Förenta staterna, 96813
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu, Hawaii, Förenta staterna, 96813
        • Queen's Cancer Cenrer - POB I
      • Honolulu, Hawaii, Förenta staterna, 96813
        • Straub Clinic and Hospital
      • Honolulu, Hawaii, Förenta staterna, 96813
        • University of Hawaii Cancer Center
      • Honolulu, Hawaii, Förenta staterna, 96817
        • Hawaii Cancer Care Inc-Liliha
      • Honolulu, Hawaii, Förenta staterna, 96817
        • Kuakini Medical Center
      • Honolulu, Hawaii, Förenta staterna, 96817
        • Queen's Cancer Center - Kuakini
      • Honolulu, Hawaii, Förenta staterna, 96826
        • Kapiolani Medical Center for Women and Children
      • Honolulu, Hawaii, Förenta staterna, 96813
        • Island Urology
      • Lihue, Hawaii, Förenta staterna, 96766
        • Wilcox Memorial Hospital and Kauai Medical Clinic
      • ‘Aiea, Hawaii, Förenta staterna, 96701
        • Pali Momi Medical Center
      • ‘Aiea, Hawaii, Förenta staterna, 96701
        • Queen's Cancer Center - Pearlridge
      • ‘Aiea, Hawaii, Förenta staterna, 96701
        • The Cancer Center of Hawaii-Pali Momi
      • ‘Aiea, Hawaii, Förenta staterna, 96701
        • Hawaii Cancer Care - Savio
    • Idaho
      • Boise, Idaho, Förenta staterna, 83706
        • Saint Alphonsus Cancer Care Center-Boise
      • Caldwell, Idaho, Förenta staterna, 83605
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Förenta staterna, 83814
        • Kootenai Health - Coeur d'Alene
      • Emmett, Idaho, Förenta staterna, 83617
        • Walter Knox Memorial Hospital
      • Meridian, Idaho, Förenta staterna, 83642
        • Idaho Urologic Institute-Meridian
      • Nampa, Idaho, Förenta staterna, 83686
        • Saint Alphonsus Medical Center-Nampa
      • Post Falls, Idaho, Förenta staterna, 83854
        • Kootenai Clinic Cancer Services - Post Falls
      • Sandpoint, Idaho, Förenta staterna, 83864
        • Kootenai Cancer Clinic
    • Illinois
      • Chicago, Illinois, Förenta staterna, 60612
        • John H Stroger Jr Hospital of Cook County
      • Danville, Illinois, Förenta staterna, 61832
        • Carle on Vermilion
      • Effingham, Illinois, Förenta staterna, 62401
        • Carle Physician Group-Effingham
      • Mattoon, Illinois, Förenta staterna, 61938
        • Carle Physician Group-Mattoon/Charleston
      • Urbana, Illinois, Förenta staterna, 61801
        • Carle Cancer Center
      • Urbana, Illinois, Förenta staterna, 61801
        • The Carle Foundation Hospital
    • Louisiana
      • New Orleans, Louisiana, Förenta staterna, 70121
        • Ochsner Medical Center Jefferson
    • Montana
      • Anaconda, Montana, Förenta staterna, 59711
        • Community Hospital of Anaconda
      • Billings, Montana, Förenta staterna, 59101
        • Billings Clinic Cancer Center
      • Bozeman, Montana, Förenta staterna, 59715
        • Bozeman Deaconess Hospital
      • Great Falls, Montana, Förenta staterna, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Förenta staterna, 59405
        • Benefis Healthcare- Sletten Cancer Institute
      • Helena, Montana, Förenta staterna, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Förenta staterna, 59901
        • Kalispell Regional Medical Center
      • Missoula, Montana, Förenta staterna, 59804
        • Community Medical Hospital
    • New Mexico
      • Albuquerque, New Mexico, Förenta staterna, 87102
        • University of New Mexico Cancer Center
    • Oregon
      • Baker City, Oregon, Förenta staterna, 97814
        • Saint Alphonsus Medical Center-Baker City
      • Ontario, Oregon, Förenta staterna, 97914
        • Saint Alphonsus Medical Center-Ontario
    • South Carolina
      • Charleston, South Carolina, Förenta staterna, 29425
        • Medical University of South Carolina
    • Virginia
      • Richmond, Virginia, Förenta staterna, 23235
        • VCU Massey Cancer Center at Stony Point
      • Richmond, Virginia, Förenta staterna, 23298
        • Virginia Commonwealth University/Massey Cancer Center
    • Wisconsin
      • Marshfield, Wisconsin, Förenta staterna, 54449
        • Marshfield Medical Center-Marshfield
    • Wyoming
      • Cody, Wyoming, Förenta staterna, 82414
        • Billings Clinic-Cody
      • Sheridan, Wyoming, Förenta staterna, 82801
        • Welch Cancer Center
      • Tamuning, Guam, 96913
        • FHP Health Center-Guam
      • San Juan, Puerto Rico, 00902
        • Pan American Center for Oncology Trials LLC

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Beskrivning

Inclusion Criteria:

  • Newly diagnosed with stage 0-III breast cancer
  • Eligible patients must be planning breast surgery as a component of their definitive treatment
  • Patients with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) are not eligible for this study
  • Patients with hearing impairment requiring the use of an interpreter are not eligible for this study
  • Patients must be able to speak English with the fluency required to have a direct discussion around treatment decision-making (i.e. without interpreter)
  • CLINIC STAKEHOLDER (SURGEONS AND CLINIC STAFF): Breast surgeon(s) and nursing staff, medical assistant, or mid-level provider at each participating clinic who participates in the care of patients newly diagnosed with breast cancer
  • INSTITUTIONAL: 10 clinics that annually provide surgical care for 120-300 patients newly diagnosed with breast cancer will be selected to participate in this study
  • INSTITUTIONAL: Surgeons at eligible clinics must consent to the study as a requirement for site participation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Hälsovårdsforskning
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Arm I (surgical consultation)

Prior to institutional crossover, participants receive care as per usual care.

Usual Care

Experimentell: Arm II (web-based breast cancer surgery decision aid)

Following a 10 week implementation period, at the time of institutional crossover, participants will receive a web-based decision aid prior to the surgical consultation..

Usual Care

Web-based decision aid received prior to the surgical consultation

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient Power: Self-efficacy in Patient Physician Interactions
Tidsram: 3 weeks

Power is defined as patients' self-perceived capacity to influence the decision-making encounter. This construct is measured using the Patient's Self-Efficacy in Patient-Physician Interactions (PEPPI)-5 point scale; the primary outcome measure is a total score ranging from 5-25, where higher scores indicate increased self-efficacy. The patient completes the PEPPI-5 questionnaire within 3 weeks post-surgical consultation.

3 weeks
Patient Power: Active Patient Participation
Tidsram: 1 day

Power is also separately measured by the validated Active Patient Participation Behaviors System to assess active patient participation during the surgeon consultation and is measured off the audio-recording of the consultation; a summary measure of patient's active involvement in the interaction is coded by the study team and represents a total count of patients' communicative behaviors (i.e., count of patient asking questions, count of patient assertive responses and count of patient expressions of concern) ranging from 0-114, where higher scores indicate increased active patient participation. The consultation for a patient will typically be study day 1 (day of registration).

1 day

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient Knowledge
Tidsram: Up to 3 weeks

Patient knowledge is measured from 5 knowledge questions in the Decision Quality Instrument-Breast Surgery survey, with a percent correct recorded as the secondary outcome measure, ranging from 0-100%. The patient completes the Decision Quality Instrument-Breast Surgery survey within 3 weeks post-surgical consultation.

Up to 3 weeks
Percentage of Concordant Between Surgery Received and Patient Treatment Preference
Tidsram: Up to 3 weeks

This binary outcome indicates whether the surgery received (mastectomy or lumpectomy) was concordant with the patient's treatment preference. Patient's goals/concerns (keep the breast, remove the breast for peace of mind, avoid radiation), rated from 0 (not at all important) to 10 (extremely important), and treatment preference (lumpectomy only, lumpectomy and radiation, mastectomy, other surgery, or not sure) are measured with the Decision Quality Instrument (DQI)-Breast Surgery survey, completed within 3 weeks post-consultation. Concordance is derived using the method of Sepucha et al. (2012): (1) estimate a predicted probability (pp) of surgery preference from a multivariable logistic regression model with patient's goals/concerns and stage as independent variables; (2) classify patients as concordant if pp >= 0.5 and mastectomy was received, or pp < 0.5 and lumpectomy was received; and (3) calculate the percentage of concordant.

Up to 3 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studiestol: Heather B. Neuman,, MD, MS, University of Wisconsin, Madison

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

5 juni 2019

Primärt slutförande (Faktisk)

26 januari 2023

Avslutad studie (Faktisk)

30 maj 2023

Studieregistreringsdatum

Först inskickad

30 november 2018

Först inskickad som uppfyllde QC-kriterierna

4 december 2018

Första postat (Faktisk)

5 december 2018

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • A231701CD
  • NCI-2018-00643 (Registeridentifierare: NCI Clinical Trial Reporting Program)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Tidsram för IPD-delning

Beginning 6 to 12 months following article publication.

Kriterier för IPD Sharing Access

Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • ICF

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera